Bicycle Therapeutics plc (NASDAQ:BCYC) Receives $33.25 Average Price Target from Brokerages

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $33.25.

A number of equities analysts have recently commented on BCYC shares. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. B. Riley cut their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. JMP Securities decreased their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday, January 13th.

Insider Buying and Selling

In other news, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the transaction, the chief accounting officer now directly owns 19,241 shares in the company, valued at approximately $483,141.51. This represents a 24.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 985,397 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the purchase, the director now owns 9,537,643 shares of the company’s stock, valued at approximately $131,237,967.68. The trade was a 11.52 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 33,933 shares of company stock valued at $549,501 in the last quarter. Company insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Large investors have recently modified their holdings of the stock. Assetmark Inc. bought a new position in Bicycle Therapeutics during the 3rd quarter worth approximately $34,000. GAMMA Investing LLC lifted its holdings in Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after buying an additional 1,038 shares during the last quarter. Avior Wealth Management LLC bought a new position in Bicycle Therapeutics during the 4th quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. lifted its holdings in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after buying an additional 2,918 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after buying an additional 1,782 shares during the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Trading Down 2.1 %

Shares of BCYC opened at $12.61 on Tuesday. Bicycle Therapeutics has a twelve month low of $12.17 and a twelve month high of $28.67. The firm has a market capitalization of $870.72 million, a P/E ratio of -3.83 and a beta of 0.93. The stock’s fifty day simple moving average is $15.38 and its 200 day simple moving average is $20.70.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.